# Intellia Therapeutics, Inc.: overview

NTLA · Nasdaq · CIK 1652130 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntla.md) · [Financials](/companies/ntla/financials.md) · [Filings](/companies/ntla/filings.md) · [Insiders](/companies/ntla/insiders.md)

Latest reported revenue: [$7.7m](/filings/0001193125-26-337952.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-337952).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9.1](/filings/0001193125-25-269680.md) | [12.9 d](/filings/0001193125-26-076550.md) | [16.6](/filings/0001193125-26-215740.md) | [14.2](/filings/0001193125-26-337952.md) | [13.8](/filings/0001193125-25-269680.md) | [23.0 d](/filings/0001193125-26-076550.md) | [15.0](/filings/0001193125-26-215740.md) | [7.7](/filings/0001193125-26-337952.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1589.0%)](/filings/0001193125-25-269680.md) | [(1059.9%) d](/filings/0001193125-26-076550.md) | [(726.6%)](/filings/0001193125-26-215740.md) | [(772.2%)](/filings/0001193125-26-337952.md) | [(808.9%)](/filings/0001193125-25-269680.md) | [(428.9%) d](/filings/0001193125-26-076550.md) | [(668.1%)](/filings/0001193125-26-215740.md) | [(1472.3%)](/filings/0001193125-26-337952.md) |
| Net margin | % | [(1489.5%)](/filings/0001193125-25-269680.md) | [(1001.2%) d](/filings/0001193125-26-076550.md) | [(687.6%)](/filings/0001193125-26-337952.md) | [(710.8%)](/filings/0001193125-26-337952.md) | [(735.2%)](/filings/0001193125-25-269680.md) | [(416.2%) d](/filings/0001193125-26-076550.md) | [(639.5%)](/filings/0001193125-26-337952.md) | [(1392.3%)](/filings/0001193125-26-337952.md) |
| Diluted EPS | $ per share | [(1.34)](/filings/0001193125-25-269680.md) | not reported | [(1.10)](/filings/0001193125-26-215740.md) | [(0.98)](/filings/0001193125-26-337952.md) | [(0.92)](/filings/0001193125-25-269680.md) | not reported | [(0.81)](/filings/0001193125-26-215740.md) | [(0.80)](/filings/0001193125-26-337952.md) |
| Free cash flow | $m | [(86.1) d](/filings/0001193125-25-269680.md) | [(86.2) d](/filings/0001193125-26-076550.md) | [(150)](/filings/0001193125-26-215740.md) | [(99.9) d](/filings/0001193125-26-337952.md) | [(76.9) d](/filings/0001193125-25-269680.md) | [(69.4) d](/filings/0001193125-26-076550.md) | [(117)](/filings/0001193125-26-215740.md) | [(84.9) d](/filings/0001193125-26-337952.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [33.1](/filings/0000950170-24-018736.md) | [52.1](/filings/0000950170-25-029007.md) | [36.3](/filings/0001193125-26-076550.md) | [57.9](/filings/0001193125-26-076550.md) | [67.7](/filings/0001193125-26-076550.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(810.4%)](/filings/0000950170-24-018736.md) | [(879.0%)](/filings/0000950170-25-029007.md) | [(1420.5%)](/filings/0001193125-26-076550.md) | [(923.1%)](/filings/0001193125-26-076550.md) | [(651.7%)](/filings/0001193125-26-076550.md) |
| Net margin | % | [(810.5%)](/filings/0000950170-24-018736.md) | [(909.8%)](/filings/0000950170-25-029007.md) | [(1326.5%)](/filings/0001193125-26-076550.md) | [(896.8%)](/filings/0001193125-26-076550.md) | [(609.9%)](/filings/0001193125-26-076550.md) |
| Diluted EPS | $ per share | [(3.78)](/filings/0000950170-24-018736.md) | [(6.16)](/filings/0000950170-25-029007.md) | [(5.42)](/filings/0001193125-26-076550.md) | [(5.25)](/filings/0001193125-26-076550.md) | [(3.81)](/filings/0001193125-26-076550.md) |
| Free cash flow | $m | [(238)](/filings/0000950170-24-018736.md) | [(347)](/filings/0000950170-25-029007.md) | [(408)](/filings/0001193125-26-076550.md) | [(355)](/filings/0001193125-26-076550.md) | [(396)](/filings/0001193125-26-076550.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ntla/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $285.5m | 16,875,684 |  | Added +2,366,437 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $260.7m | 15,409,023 |  | Added +3,253,217 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $156.3m | 9,234,987 |  | Added +2,312,311 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $124.1m | 7,332,401 |  | Added +1,109,076 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $109.0m | 6,443,323 |  | Added +715,146 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $102.0m | 6,028,586 |  | Added +944,481 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $88.6m | 5,235,348 |  | Added +529,447 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $80.8m | 4,773,034 |  | Added +2,705,812 |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $76.6m | 4,526,926 |  | New +4,526,926 |
| [REGENERON PHARMACEUTICALS, INC.](/funds/872589.md) | 2026-06-30 | $62.7m | 3,702,995 |  | Unchanged |

## Recent filings

[All 700 filings](/companies/ntla/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 20:05 ET | [8-K](/filings/0001193125-26-385194.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385194 |
| 2026-09-04 | 20:06 ET | [8-K](/filings/0001193125-26-383645.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-383645 |
| 2026-08-06 | 20:05 ET | [10-Q](/filings/0001193125-26-337952.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337952 |
| 2026-08-06 | 11:45 ET | [8-K](/filings/0001193125-26-336772.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336772 |
| 2026-06-15 | 12:52 ET | [8-K](/filings/0001193125-26-270358.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270358 |
| 2026-06-10 | 20:36 ET | [8-K](/filings/0001193125-26-265934.md) | 5.07 Shareholder vote results | 0001193125-26-265934 |
| 2026-05-11 | 11:49 ET | [10-Q](/filings/0001193125-26-215740.md) | Quarterly report, period 2026-03-31 | 0001193125-26-215740 |
| 2026-05-11 | 11:36 ET | [8-K](/filings/0001193125-26-215721.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-215721 |
| 2026-04-30 | 20:30 ET | [8-K](/filings/0001193125-26-197489.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197489 |
| 2026-04-30 | 20:10 ET | [DEF 14A](/filings/0001193125-26-197283.md) | Proxy statement, period 2026-06-09 | 0001193125-26-197283 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076550.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6536a616-7686-4db5-bd6f-b153d07d4a40)

## About the filer

- CIK: 1652130
- Tickers: NTLA
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.